# A Study of the Safety and Efficacy of Synvisc and Depo-Medrol in Patients With Osteoarthritis of the Hip

> **NCT00131326** · PHASE3 · COMPLETED · sponsor: **Genzyme, a Sanofi Company**

## Conditions studied

- Osteoarthritis, Hip
- Musculoskeletal Diseases

## Interventions

- **DEVICE:** Synvisc (hylan G-F 20)

## Key facts

- **NCT ID:** NCT00131326
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-11
- **Primary completion:** —
- **Final completion:** 2006-04
- **Target enrollment:** — (—)
- **Last updated:** 2017-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00131326

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00131326, "A Study of the Safety and Efficacy of Synvisc and Depo-Medrol in Patients With Osteoarthritis of the Hip". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT00131326. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*